Brief: Metavia Presents Pre-Clinical Data On Da-1241 Demonstrating Additive Hepatoprotective Effects In Combination With Efruxifermin At The ADA's 85Th Scientific Session
21/06/2025 14:14
June 21 (Reuters) - MetaVia Inc MTVA.O: METAVIA PRESENTS PRE-CLINICAL DATA ON DA-1241 DEMONSTRATING ADDITIVE HEPATOPROTECTIVE EFFECTS IN COMBINATION WITH EFRUXIFERMIN AT THE ADA'S 85TH SCIENTIFIC SESSION METAVIA INC - COMBINATION THERAPY DECREASES INFLAMMATORY AND FIBROTIC GENE EXPRESSION METAVIA INC - COMBINATION THERAPY REDUCES INFLAMMATORY AND FIBROTIC PROTEINS IN THE LIVER Source text: ID:nPnb83VX1a Further company coverage: MTVA.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on MetaVia
See all newsMetaVia Inc reports results for the quarter ended June 30 - Earnings Summary
MetaVia Q2 net loss widens on higher R&D spending
MetaVia Inc expected to post a loss of 82 cents a share - Earnings Preview
Brief: Biostem Technologies Announces Appointment Of Three New Members To Its Board Of Directors
MetaVia Q1 net loss widens slightly as expenses rise